Redox

Redox has become one of the most consequential healthcare technology companies to emerge from Madison, Wisconsin, building the infrastructure layer that powers data exchange between electronic health record systems and the applications that run modern healthcare. Founded in 2014 by former Epic engineers Niko Skievaski, Luke Bonney, James Lloyd, and Shobhan Thakkar, Redox identified a fundamental problem: healthcare organizations were drowning in siloed data across incompatible systems, and the industry lacked a standardized way to move patient information where it needed to go.

The company's platform functions as a universal translation layer, enabling third-party healthcare applications to connect with any EHR system through a single API. This approach eliminated the need for point-to-point integrations that were expensive to build and maintain. Healthcare software vendors could suddenly reach thousands of provider organizations without custom development for each connection, and health systems could adopt innovation without rip-and-replace IT projects.

What started as a technical solution to a technical problem evolved into a critical piece of healthcare infrastructure. Today Redox processes millions of clinical data transactions daily, serving over 12,000 healthcare organizations across payers, providers, and digital health companies. The company reached $181 million in revenue in 2024 with approximately 200 customers, demonstrating that infrastructure businesses in healthcare can achieve meaningful scale when they solve a genuinely painful problem.

The venture capital backing Redox attracted reflects the magnitude of the opportunity. .406 Ventures led the seed round in 2015, recognizing that healthcare interoperability was broken and that the former Epic engineers had deep insider knowledge of how health systems actually work. Battery Ventures, Adams Street Partners, Avenir, and RRE Ventures followed in subsequent rounds, culminating in a $45 million Series D in 2021 that positioned the company for its next phase of growth.

For healthcare technology founders, Redox represents both a proof of concept and a potential partner. The company's success demonstrates that healthcare interoperability is a real market with real customers willing to pay for solutions that actually work. At the same time, Redox's expanding platform creates opportunities for complementary solutions that can ride the interoperability infrastructure they have built.

Redox operates at the intersection of healthcare IT and interoperability, which might seem like a technical niche but represents one of the most persistent challenges in American healthcare. Health systems run dozens or hundreds of software applications that rarely communicate with each other out of the box. Epic, Oracle Health, athenahealth, and other EHR vendors each have their own data models and integration requirements. Clinical data lives in billing systems, pharmacy systems, laboratory information systems, and medical devices that were never designed to share information.

The company's investment thesis was deceptively simple: build one integration layer that speaks all the languages healthcare systems use, and healthcare organizations will pay well for the privilege of accessing their own data. Rather than selling custom integration services, Redox built a platform that could be replicated infinitely, achieving the economies of scale that enterprise software requires.

Redox's API-based approach meant that healthcare software vendors could integrate once and distribute widely. A digital health company building a chronic disease management platform could connect to all of Redox's health system customers through a single integration, rather than negotiating and building separate connections with each organization. This network effect created a self-reinforcing flywheel: more health systems on the platform made it more valuable to software vendors, which attracted more health systems.

The regulatory environment reinforced the investment thesis. The 21st Century Cures Act and associated interoperability rules created legal obligations for health information exchange, but the law did not solve the technical problem of how to actually move data at scale. Redox positioned itself as the technical compliance solution for organizations seeking to meet regulatory requirements without building custom integration infrastructure.

Healthcare organizations invest in interoperability for three reasons: regulatory compliance, care coordination, and population health management. Redox's platform addressed all three. Care coordination requires that primary care providers, specialists, hospitals, and post-acute facilities share patient information seamlessly. Population health initiatives require aggregating clinical data from across the care continuum to identify gaps in care and manage chronic disease populations. Redox made both scenarios technically feasible in a way that previous point-to-point integration approaches could not.

Redox has grown primarily through equity financing, raising capital across nine funding rounds that chart the company's evolution from early-stage startup to market leader. The company's most significant financing event was the $45 million Series D in April 2021, led by Adams Street Partners with participation from existing investors Avenir, Battery Ventures, and .406 Ventures, along with new investor RRE Ventures. This round came at a point when Redox had demonstrated product-market fit and was scaling its enterprise sales organization.

Prior to the Series D, Redox raised a $33 million Series C in April 2019 that accelerated investment in platform capabilities and geographic expansion. The Series B of $9 million in January 2017, led by RRE Ventures, helped the company build out its sales and marketing functions after years of focusing primarily on product development. The early-stage funding trajectory reflects a company that raised conservatively and demonstrated meaningful milestones between rounds.

The company's revenue growth to $181 million in 2024 from approximately $50 million a few years earlier demonstrates the leverage inherent in a platform-based interoperability business. As more health systems connected to the platform and more software vendors integrated through Redox's API, the company could grow revenue significantly faster than costs, approaching the SaaS unit economics profile that healthcare infrastructure businesses require.

Redox's investor syndicate reflects healthcare-focused venture capital at its most deliberate. .406 Ventures, a Boston-based firm with deep healthcare expertise, identified Redox at the earliest stage and provided not just capital but operational guidance on building a healthcare enterprise sales motion. Battery Ventures brought scale portfolio experience from enterprise software businesses outside healthcare. Adams Street Partners, with its primary fund focus, signaled the company's progression toward growth-stage status.

As a healthcare technology infrastructure company rather than a traditional venture investor, Redox's portfolio consists of the healthcare organizations and software vendors that use its integration platform. The company's customer base includes large health systems like those that have standardized on Redox for EHR integration across their employed physician networks and ambulatory care facilities, digital health companies building next-generation clinical applications, and health plans seeking to integrate clinical data for population health analytics.

Healthcare organizations using Redox span the full continuum of care: academic medical centers, community hospitals, independent physician practices, post-acute care facilities, and retail health clinics. The platform processes clinical data including admissions, discharges, and transfers, laboratory results, medication histories, and clinical notes from both structured and unstructured sources.

Redox's partnership with Epic represents a significant competitive moat. Rather than treating Epic as just another EHR to integrate with, Redox built deep compatibility with Epic's data models and integration mechanisms, enabling its customers to achieve bidirectional data exchange with one of the largest EHR platforms in healthcare. Similar partnerships with Oracle Health and athenahealth extend the company's reach across the most widely deployed EHR systems.

The company's digital health customers include many of the most well-funded healthcare technology companies building on top of Redox's infrastructure. These include companies in chronic disease management, remote patient monitoring, clinical decision support, and care coordination. Redox's platform enables these companies to deploy their applications across hundreds of health system customers in a fraction of the time and cost that custom integrations would require.

Redox's expansion into workflows beyond simple data exchange reflects the company's ambition to become the full stack interoperability layer for healthcare. The 2025 expansion of the core platform introduced smarter interoperability workflows that go beyond simple data transmission to include data transformation, validation, and enrichment capabilities that help healthcare organizations actually use the data they receive.

Strategic partnerships like the alliance with Kno2, announced in October 2025, extend Redox's capabilities in nationwide health information exchange. Kno2's direct messaging and care coordination capabilities complement Redox's API-based integration approach, creating an end-to-end interoperability offering that serves healthcare organizations from point-to-point connection to cross-organization data sharing.

Healthcare technology companies seeking to partner with Redox should understand that Redox evaluates opportunities through the lens of interoperability complementarity. The company is most interested in solutions that expand the utility of clinical data exchange rather than competing directly with the integration infrastructure layer that Redox has built.

Strong product-market fit indicators are essential. Redox's enterprise sales team serves healthcare organizations that are evaluating digital health solutions, and the company's partnership can accelerate go-to-market for solutions that have already demonstrated traction with health system customers. Companies with referenceable customers at scale, proven clinical workflow integration, and demonstrated outcomes data will find a receptive audience.

The founding team matters significantly in Redox's evaluation process. Healthcare technology is a relationship-driven business where trust in the team determines whether a partnership becomes a strategic priority or a transactional vendor engagement. Founders with clinical backgrounds, previous healthcare enterprise experience, or deep domain expertise in the specific use case their company addresses will have an advantage in discussions with Redox's partnership team.

Financial metrics including recurring revenue metrics, net revenue retention, and gross margin profile help Redox assess the long-term viability of potential partners. Companies that have achieved product-market fit with strong SaaS unit economics demonstrate the operational discipline that Redox values in its ecosystem participants. ARR growth rate matters less than the consistency and predictability of that growth.

Technical fit with Redox's API infrastructure is a prerequisite for partnership discussions. Companies building on standard healthcare data formats, particularly those already leveraging FHIR-based architectures, will find easier integration paths than those requiring custom development work on Redox's platform. The company's technical team evaluates each potential partner's architecture to ensure alignment before committing to a partnership.

Engaging with Redox for partnership discussions requires a clear articulation of how your healthcare technology solution complements the company's interoperability platform. Unlike traditional venture capital firms that evaluate companies primarily on financial metrics and market opportunity, Redox's partnership process focuses on technical integration fit and clinical workflow value.

The Redox website at redoxengine.com provides the primary entry point for partnership inquiries, with dedicated pages for software vendor partnerships and health system connections. Vendor partnership inquiries should include information about your company's solution, target health system customers, current integration approach, and the specific interoperability challenges you are seeking to address through the Redox platform.

Healthcare technology founders who have existing relationships with Redox's investor syndicate may benefit from warm introductions through firms like .406 Ventures or Battery Ventures. These investors often facilitate connections between their portfolio companies and strategic partners, recognizing that interoperability infrastructure investments create value for the entire ecosystem.

When evaluating partnership readiness, Redox typically wants to understand your company's current integration infrastructure, the volume and types of clinical data you need to exchange, your target health system customers, and your projected integration timeline. Companies that come to partnership discussions with clear use cases and technical specifications will move through the evaluation process more quickly than those seeking general guidance on integration strategy.

Following an initial partnership discussion, Redox's technical team conducts a more detailed evaluation of integration requirements, including API compatibility assessment, data mapping requirements, and workflow integration specifications. The partnership timeline from initial inquiry to active integration typically spans several months for companies new to the platform.

Long-term partnership success with Redox requires ongoing technical collaboration as healthcare interoperability standards evolve and the regulatory environment changes. Companies that view the partnership as a strategic relationship rather than a transactional integration vendor engagement will find Redox to be a more engaged and supportive partner.

Healthcare technology companies building on Redox's platform still require the financial foundation that any enterprise software business needs. Investors and strategic partners evaluating your company will scrutinize your revenue trajectory, gross margins, and path to profitability with the same rigor applied to non-healthcare software businesses.

Healthcare enterprise sales cycles are notoriously long, often extending 12 to 18 months from initial contact to signed contract for large health system deployments. This reality makes financial planning particularly challenging for healthcare technology companies, as significant upfront investment in sales and product development precedes revenue recognition. Founders should ensure their financial models account for the extended sales cycles that characterize healthcare enterprise sales.

Working with a fractional CFO experienced in healthcare technology finance can dramatically improve your company's readiness for strategic partnership discussions and equity financing. Healthcare-specific financial considerations including HIPAA compliance costs, FDA regulatory pathway expenses, and healthcare-specific revenue recognition rules require specialized knowledge that generalist financial controllers may lack.

Our team has guided numerous healthcare technology companies through strategic planning, capital raise preparation, and financial model development. We understand the metrics that matter to healthcare technology investors and strategic partners, including net revenue retention, clinical outcomes data, and the relationship between ARR benchmarks growth and the cost of customer acquisition in healthcare enterprise sales.

Financial projections for healthcare technology companies should incorporate realistic assumptions about health system budget cycles, which typically align with fiscal years that end in June or September, and the impact of regulatory changes on market timing. Redox's strategic partners and their investors will challenge projections that do not account for these healthcare-specific realities.

Understanding your key performance indicators at the clinical and operational level is increasingly important for healthcare technology companies. Beyond standard SaaS financial metrics, healthcare technology companies should be prepared to discuss clinical workflow integration rates, provider adoption metrics, and patient outcome data that demonstrates the clinical value your solution delivers.

Whether you are preparing your healthcare technology company for strategic partnership with Redox or broader fundraising from healthcare-focused venture capital firms, having professional financials and a clear articulation of your clinical value proposition will set you apart from competitors. Our team has helped healthcare technology companies at every stage, from seed financing through Series D and beyond, understand what investors and partners look for in financial presentations and strategic narratives.

Exploring other venture capital firms? Our comprehensive collection of VC firm reviews covers hundreds of investors across all stages and sectors.

Each review provides detailed information about investment criteria, portfolio companies, and tips for securing funding. Whether you are looking for seed-stage investors or growth equity firms, you will find valuable insights in our VC firm guides.

Finding the right investor for your startup is crucial to your success. Take the time to research potential investors and understand their investment thesis before reaching out.

Our guides cover major venture capital firms as well as emerging managers that may be a better fit for your company's specific needs and stage.